부신경절종 시장 규모는 향후 수년간 강력한 성장이 예상될 예정입니다. 또한 신흥 시장의 헬스케어 액세스 개선 등에 기인한다고 생각됩니다. 이 기간에 예상되는 주요 동향에는 표적요법의 진전, 방사성의약품의 확대, 면역요법 접근의 대두, 진단에 있어서의 인공지능(AI)의 이용 강화, 저침습 수술기술의 개발 등이 있습니다.
종양학 연구 및 의료에 대한 투자의 확대가 향후 몇 년간의 종양학 연구 및 의료 시장 확대의 원동력이 될 것으로 예측됩니다. 투자 증가는 세계의 암 이환율 상승, 정밀의료 진보, 혁신적인 치료법에 대한 수요 증가, 임상 검사 확대, 정부 및 민간 자금 제공 이니셔티브, 표적 요법 및 면역 요법의 개발에 의해 촉진되고 있습니다. 선택의 강화, 보다 효과적인 약제의 임상 검사에의 자금 제공, 소아암 치료의 인프라 강화, 질환의 생물학적 성질과 진행의 이해를 깊게 하기 위한 혁신적 연구의 촉진 등에 의해 부신경절종의 진보를 지지하고 있습니다. IQVIA는 2023년 세계의 암 의료에 대한 지출이 2022년부터 250억 달러 증가한 2,230억 달러로 증가하고, 2028년에는 4,090억 달러에 이를 것으로 예측하고 있다고 보고했습니다.
부신경절종 시장의 주요 기업은 경구 저산소 유도 인자-2α(HIF-2a) 억제제와 같은 고급 치료의 개발을 선호하고 환자에게 표적 치료 옵션을 제공합니다. 요인인 HIF-2a 활성을 저해하는 표적 치료이며, 이로써 부신경절종과 같은 상태에서의 암의 진행을 지연시킵니다. 2025년 1월, 미국에 본사를 둔 바이오 제약 회사인 머크는 미국 정부 기관인 미국 식품의약국(FDA)으로부터 웰리렉(벨주티판)에 대한 추가 신약 신청이 우선 검토를 받았다고 발표했습니다. 웰리렉은 진행성, 절제 불가능성 또는 전이성 갈색세포종과 부교세포종(PPGL)을 가진 성인 및 소아 환자(12세 이상)를 대상으로 합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계의 부신경절종 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
- 최종 이용 산업의 분석
- 세계의 부신경절종 시장 : 성장률 분석
- 세계의 부신경절종 시장 실적 : 규모와 성장, 2019-2024년
- 세계의 부신경절종 시장 예측 : 규모와 성장, 2024-2029년, 2034년
- 세계의 부신경절종 전체 시장 규모(TAM)
제6장 시장 세분화
- 세계의 부신경절종 시장 : 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
- 교감신경성부신경절종
- 부교감신경부신경절종
- 경동맥방 신경절종
- 경부부신경절종
- 경정맥방 신경절종
- 분비성 부신경절종
- 측두엽방 신경절종
- 세계의 부신경절종 시장 : 원인 부위별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
- 두경부
- 복부
- 골반
- 기타 원인 부위
- 세계의 부신경절종 시장 : 치료 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
- 펩티드 수용체 방사성핵종요법
- 수술
- 화학요법
- 방사선치료
- 기타 치료 유형
- 세계의 부신경절종 시장 : 유통 채널별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
- 병원 약국
- 약국과 약국
- 온라인 약국
- 세계의 부신경절종 시장 : 최종 사용자별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
- 병원
- 전문 클리닉
- 암 연구 기관
- 기타
- 세계의 부신경절종 시장 : 교감신경성 부신경절종별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
- 부신교감신경부신경절종
- 부신외교감신경절종
- 세계의 부신경절종 시장 : 부교감 신경부신경절종별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
- 두경부 부교감 신경절종
- 흉부 부교감 신경방 신경절종
- 세계의 부신경절종 시장 : 경동맥부신경절종별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
- 편측 경동맥방 신경절종
- 양측 경동맥방 신경절종
- 세계의 부신경절종 시장 : 경부부신경절종별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
- 미주 신경절종
- 설하신경절종
- 세계의 부신경절종 시장 : 경정맥부신경절종별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
- A형
- 유형 B
- 유형 C
- 유형 D
- 세계의 부신경절종 시장 : 분비성 부신경절종별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
- 카테콜아민 분비성 부신경절종
- 비카테콜아민 분비성 부신경절종
- 세계의 부신경절종 시장 : 측두엽방 신경절종별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
- 고실부신경절종
- 유양 돌기방 신경절종
제7장 지역별/국가별 분석
- 세계의 부신경절종 시장 : 지역별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
- 세계의 부신경절종 시장 : 국가별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
- 부신경절종 시장 : 경쟁 구도
- 부신경절종 시장 : 기업 프로파일
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- Mount Sinai
- Penn Medicine
- Stanford Health Care
제31장 기타 주요 기업 및 혁신 기업
- St. Jude Children's Research Hospital
- UT Health San Antonio
- The University of Chicago Medical Center
- Fred Hutchinson Cancer Center
- Florida Cancer Specialists & Research Institute
- Invitae Corp.
- Clinigen Group plc
- Fulgent Genetics
- Dana-Farber Cancer Institute Inc.
- Oncology Hematology Care Inc.
- Enterome
- National Institutes of Health Clinical Center
- Progenics Pharmaceuticals Inc.
- Pheo Para Alliance
- Saint John's Cancer Institute
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 전략
- 부신경절종 시장, 2029년 : 새로운 기회를 제공하는 국가
- 부신경절종 시장, 2029년 : 새로운 기회를 제공하는 부문
- 부신경절종 시장, 2029년 : 성장 전략
제36장 부록
SHW
Paraganglioma is a rare neuroendocrine tumor that arises from paraganglia, clusters of cells associated with the autonomic nervous system. These tumors are typically found in the head, neck, chest, or abdomen and may produce excess hormones, posing a risk of malignancy. Early diagnosis is crucial for effective management and preventing complications.
The main types of paraganglioma include sympathetic, parasympathetic, carotid, cervical, jugular, secretory, and temporal paragangliomas. Sympathetic paragangliomas, which develop in the sympathetic nervous system, often produce catecholamines. These tumors originate from various locations, such as the head and neck, abdomen, pelvis, and other areas. Treatment options include peptide receptor radionuclide therapy, surgery, chemotherapy, radiation therapy, and other approaches. These treatments are distributed through hospital pharmacies, drug stores, retail pharmacies, and online pharmacies, catering to end-users such as hospitals, specialty clinics, and cancer research institutes.
The paraganglioma market research report is one of a series of new reports from The Business Research Company that provides paraganglioma market statistics, including the paraganglioma industry global market size, regional shares, competitors with the paraganglioma market share, detailed paraganglioma market segments, market trends, and opportunities, and any further data you may need to thrive in the paraganglioma industry. This paraganglioma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The paraganglioma market size has grown strongly in recent years. It will grow from $2.89 billion in 2024 to $3.03 billion in 2025 at a compound annual growth rate (CAGR) of 5.0%. The growth in the historic period can be attributed to advancements in diagnostic imaging, increased awareness and screening programs, regulatory approvals for targeted therapies, the expansion of specialized treatment centers, and progress in genetic testing.
The paraganglioma market size is expected to see strong growth in the next few years. It will grow to $3.64 billion in 2029 at a compound annual growth rate (CAGR) of 4.7%. The growth in the forecast period can be attributed to emerging targeted therapies and immunotherapies, the expansion of radiopharmaceuticals, the rising prevalence of genetic diseases, increasing investments in rare disease research, and improved healthcare access in emerging markets. Major trends expected during this period include advancements in targeted therapies, the expansion of radiopharmaceuticals, the rise of immunotherapy approaches, enhanced use of artificial intelligence (AI) in diagnostics, and the development of minimally invasive surgical techniques.
The growing investments in oncology research and medicine are expected to drive the expansion of the paraganglioma market in the coming years. Investments in oncology research and medicine refer to financial commitments made by governments, pharmaceutical companies, research institutions, and private investors to advance cancer prevention, diagnosis, and treatment. The increase in such investments is fueled by the rising global cancer burden, advancements in precision medicine, growing demand for innovative therapies, expansion of clinical trials, government and private funding initiatives, and the development of targeted and immunotherapy treatments. These investments support advancements in paraganglioma by improving early diagnosis, enhancing treatment options such as targeted therapies and immunotherapy, funding clinical trials for more effective drugs, strengthening pediatric cancer care infrastructure, and fostering innovative research to better understand the disease's biology and progression. For instance, in May 2024, IQVIA, an India-based information technology company specializing in advanced analytics, reported that global spending on cancer medicine increased to $223 billion in 2023, a $25 billion rise from 2022, and is projected to reach $409 billion by 2028. As a result, the increasing investments in oncology research and medicine are fueling the growth of the paraganglioma market.
Leading companies in the paraganglioma market are prioritizing the development of advanced therapies such as oral hypoxia-inducible factor-2 alpha (HIF-2a) inhibitors to provide targeted treatment options for patients. An oral HIF-2a inhibitor is a targeted therapy that inhibits HIF-2a activity, a key factor in tumor growth under low-oxygen conditions, thereby slowing cancer progression in conditions such as paraganglioma. For example, in January 2025, Merck, a US-based biopharmaceutical company, announced that its supplemental new drug application for Welireg (belzutifan) received priority review from the U.S. Food and Drug Administration (FDA), a US-based government agency. Welireg is intended for adult and pediatric patients (12 years and older) with advanced, unresectable, or metastatic pheochromocytoma and paraganglioma (PPGL). The supplemental new drug application (sNDA) is supported by objective response rate (ORR) and duration of response (DOR) data from the Phase 2 LITESPARK-015 trial.
In January 2022, Exact Sciences Corp., a US-based molecular diagnostics company, acquired PreventionGenetics for an undisclosed amount. This acquisition was aimed at expanding Exact Sciences' hereditary cancer testing capabilities, increasing access to early detection and personalized treatment options. PreventionGenetics, a US-based clinical genetic testing laboratory, specializes in genetic testing for hereditary paraganglioma-pheochromocytoma (PGL/PCC) syndrome.
Major players in the paraganglioma market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Mount Sinai, Penn Medicine, Stanford Health Care, St. Jude Children's Research Hospital, UT Health San Antonio, The University of Chicago Medical Center, Fred Hutchinson Cancer Center, Florida Cancer Specialists & Research Institute, Invitae Corp., Clinigen Group plc, Fulgent Genetics, Dana-Farber Cancer Institute Inc., Oncology Hematology Care Inc., Enterome, National Institutes of Health Clinical Center, Progenics Pharmaceuticals Inc., Pheo Para Alliance, Saint John's Cancer Institute.
North America was the largest region in the paraganglioma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in paraganglioma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the paraganglioma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The paraganglioma market consists of revenues earned by entities by providing services such as diagnosis & screening services, post-treatment and support services, and clinical trials and research services. The market value includes the value of related goods sold by the service provider or included within the service offering. The paraganglioma market also includes sales of imaging kits, alpha-adrenergic blockers, and supportive care products. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Paraganglioma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on paraganglioma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for paraganglioma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The paraganglioma market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Type: Sympathetic Paragangliomas; Parasympathetic Paragangliomas; Caroid Paragangliomas; Cervical Paragangliomas; Jugular Paragangliomas; Secretory Paragangliomas; Temporal Paragangliomas
- 2) By Origin: Head And Neck; Abdomen; Pelvis; Other Origins
- 3) By Treatment Type: Peptide Receptor Radionuclide Therapy; Surgery; Chemotherapy; Radiation Therapy; Other Treatment Types
- 4) By Distribution Channel: Hospital Pharmacies; Drug Stores And Retail Pharmacies; Online Pharmacies
- 5) By End-User: Hospitals; Specialty Clinics; Cancer Research Institutes; Other End-Users
- Subsegments:
- 1) By Sympathetic Paragangliomas: Adrenal Sympathetic Paragangliomas; Extra-Adrenal Sympathetic Paragangliomas
- 2) By Parasympathetic Paragangliomas: Head And Neck Parasympathetic Paragangliomas; Thoracic Parasympathetic Paragangliomas
- 3) By Carotid Paragangliomas: Unilateral Carotid Paragangliomas; Bilateral Carotid Paragangliomas
- 4) By Cervical Paragangliomas: Vagal Paragangliomas; Hypoglossal Paragangliomas
- 5) By Jugular Paragangliomas: Type A; Type B; Type C; Type D
- 6) By Secretory Paragangliomas: Catecholamine-Secreting Paragangliomas; Non-Catecholamine-Secreting Paragangliomas
- 7) By Temporal Paragangliomas: Tympanic Paragangliomas; Mastoid Paragangliomas
- Companies Mentioned:F. Hoffmann-La Roche Ltd.; Merck & Co. Inc. ; Mount Sinai; Penn Medicine; Stanford Health Care
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Paraganglioma Market Characteristics
3. Paraganglioma Market Trends And Strategies
4. Paraganglioma Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Paraganglioma Growth Analysis And Strategic Analysis Framework
- 5.1. Global Paraganglioma PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Paraganglioma Market Growth Rate Analysis
- 5.4. Global Paraganglioma Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Paraganglioma Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Paraganglioma Total Addressable Market (TAM)
6. Paraganglioma Market Segmentation
- 6.1. Global Paraganglioma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Sympathetic Paragangliomas
- Parasympathetic Paragangliomas
- Caroid Paragangliomas
- Cervical Paragangliomas
- Jugular Paragangliomas
- Secretory Paragangliomas
- Temporal Paragangliomas
- 6.2. Global Paraganglioma Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Head And Neck
- Abdomen
- Pelvis
- Other Origins
- 6.3. Global Paraganglioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Peptide Receptor Radionuclide Therapy
- Surgery
- Chemotherapy
- Radiation Therapy
- Other Treatment Types
- 6.4. Global Paraganglioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospital Pharmacies
- Drug Stores And Retail Pharmacies
- Online Pharmacies
- 6.5. Global Paraganglioma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Specialty Clinics
- Cancer Research Institutes
- Other End-Users
- 6.6. Global Paraganglioma Market, Sub-Segmentation Of Sympathetic Paragangliomas, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Adrenal Sympathetic Paragangliomas
- Extra-Adrenal Sympathetic Paragangliomas
- 6.7. Global Paraganglioma Market, Sub-Segmentation Of Parasympathetic Paragangliomas, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Head And Neck Parasympathetic Paragangliomas
- Thoracic Parasympathetic Paragangliomas
- 6.8. Global Paraganglioma Market, Sub-Segmentation Of Carotid Paragangliomas, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Unilateral Carotid Paragangliomas
- Bilateral Carotid Paragangliomas
- 6.9. Global Paraganglioma Market, Sub-Segmentation Of Cervical Paragangliomas, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Vagal Paragangliomas
- Hypoglossal Paragangliomas
- 6.10. Global Paraganglioma Market, Sub-Segmentation Of Jugular Paragangliomas, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Type A
- Type B
- Type C
- Type D
- 6.11. Global Paraganglioma Market, Sub-Segmentation Of Secretory Paragangliomas, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Catecholamine-Secreting Paragangliomas
- Non-Catecholamine-Secreting Paragangliomas
- 6.12. Global Paraganglioma Market, Sub-Segmentation Of Temporal Paragangliomas, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Tympanic Paragangliomas
- Mastoid Paragangliomas
7. Paraganglioma Market Regional And Country Analysis
- 7.1. Global Paraganglioma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Paraganglioma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Paraganglioma Market
- 8.1. Asia-Pacific Paraganglioma Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Paraganglioma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Paraganglioma Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Paraganglioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Paraganglioma Market
- 9.1. China Paraganglioma Market Overview
- 9.2. China Paraganglioma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Paraganglioma Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Paraganglioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Paraganglioma Market
- 10.1. India Paraganglioma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Paraganglioma Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Paraganglioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Paraganglioma Market
- 11.1. Japan Paraganglioma Market Overview
- 11.2. Japan Paraganglioma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Paraganglioma Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Paraganglioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Paraganglioma Market
- 12.1. Australia Paraganglioma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Paraganglioma Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Paraganglioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Paraganglioma Market
- 13.1. Indonesia Paraganglioma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Paraganglioma Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Paraganglioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Paraganglioma Market
- 14.1. South Korea Paraganglioma Market Overview
- 14.2. South Korea Paraganglioma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Paraganglioma Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Paraganglioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Paraganglioma Market
- 15.1. Western Europe Paraganglioma Market Overview
- 15.2. Western Europe Paraganglioma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Paraganglioma Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Paraganglioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Paraganglioma Market
- 16.1. UK Paraganglioma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Paraganglioma Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Paraganglioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Paraganglioma Market
- 17.1. Germany Paraganglioma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Paraganglioma Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Paraganglioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Paraganglioma Market
- 18.1. France Paraganglioma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Paraganglioma Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Paraganglioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Paraganglioma Market
- 19.1. Italy Paraganglioma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Paraganglioma Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Paraganglioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Paraganglioma Market
- 20.1. Spain Paraganglioma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Paraganglioma Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Paraganglioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Paraganglioma Market
- 21.1. Eastern Europe Paraganglioma Market Overview
- 21.2. Eastern Europe Paraganglioma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Paraganglioma Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Paraganglioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Paraganglioma Market
- 22.1. Russia Paraganglioma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Paraganglioma Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Paraganglioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Paraganglioma Market
- 23.1. North America Paraganglioma Market Overview
- 23.2. North America Paraganglioma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Paraganglioma Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Paraganglioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Paraganglioma Market
- 24.1. USA Paraganglioma Market Overview
- 24.2. USA Paraganglioma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Paraganglioma Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Paraganglioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Paraganglioma Market
- 25.1. Canada Paraganglioma Market Overview
- 25.2. Canada Paraganglioma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Paraganglioma Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Paraganglioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Paraganglioma Market
- 26.1. South America Paraganglioma Market Overview
- 26.2. South America Paraganglioma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Paraganglioma Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Paraganglioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Paraganglioma Market
- 27.1. Brazil Paraganglioma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Paraganglioma Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Paraganglioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Paraganglioma Market
- 28.1. Middle East Paraganglioma Market Overview
- 28.2. Middle East Paraganglioma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Paraganglioma Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Paraganglioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Paraganglioma Market
- 29.1. Africa Paraganglioma Market Overview
- 29.2. Africa Paraganglioma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Paraganglioma Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Paraganglioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Paraganglioma Market Competitive Landscape And Company Profiles
- 30.1. Paraganglioma Market Competitive Landscape
- 30.2. Paraganglioma Market Company Profiles
- 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Mount Sinai Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Penn Medicine Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Stanford Health Care Overview, Products and Services, Strategy and Financial Analysis
31. Paraganglioma Market Other Major And Innovative Companies
- 31.1. St. Jude Children's Research Hospital
- 31.2. UT Health San Antonio
- 31.3. The University of Chicago Medical Center
- 31.4. Fred Hutchinson Cancer Center
- 31.5. Florida Cancer Specialists & Research Institute
- 31.6. Invitae Corp.
- 31.7. Clinigen Group plc
- 31.8. Fulgent Genetics
- 31.9. Dana-Farber Cancer Institute Inc.
- 31.10. Oncology Hematology Care Inc.
- 31.11. Enterome
- 31.12. National Institutes of Health Clinical Center
- 31.13. Progenics Pharmaceuticals Inc.
- 31.14. Pheo Para Alliance
- 31.15. Saint John's Cancer Institute
32. Global Paraganglioma Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Paraganglioma Market
34. Recent Developments In The Paraganglioma Market
35. Paraganglioma Market High Potential Countries, Segments and Strategies
- 35.1 Paraganglioma Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Paraganglioma Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Paraganglioma Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
